OPHTHALMIC THERAPEUTIC COMPOSITION
    2.
    发明公开
    OPHTHALMIC THERAPEUTIC COMPOSITION 有权
    Verwendung vom Pentapeptid PHSRN在opthalmischen Formulierungen

    公开(公告)号:EP1586324A1

    公开(公告)日:2005-10-19

    申请号:EP03786242.2

    申请日:2003-12-24

    摘要: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (Pro-His-Ser-Arg-Asn), or Ac-Pro-His-Ser-Arg-Asn-NH 2 , which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

    摘要翻译: 目的是找到纤维连接蛋白的最小活性表达位点,阐明该最小单位相对于眼科领域的作用,并提供具有该最小单位作为有效成分的眼科学组合物。 本发明提供了一种眼科学组合物,特别是含有肽PHSRN(Pro-His-Ser-Arg-Asn)或Ac-Pro-His-Ser-Arg-Asn-NH 2的角膜病症治疗剂,其为 衍生物,或其盐作为药物作为有效成分。 优选的剂型是眼用制剂。